International Pharmaceutical Industry (IPI) is a peer-reviewed journal offering the pharmaceutical and biopharmaceutical industries insight into important scientific, technological, regulatory, and business topics. The publication reaches a global audience of professionals involved in outsourcing management for this industry.
With multiple original reference biologics coming off patent between 2018 and 2023, biosimilar manufacturers now have a major window of opportunity. George I’ons, Head of Product Strategy and Insight at Owen Mumford Pharmaceutical Services, examines the key factors that will drive new biosimilar uptake and what this means for the market share of original biologics.